Navigation Links
Molecular imaging finds novel way to knock down breast cancer
Date:6/9/2014

St. Louis, Mo. (June 9, 2014) For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cellsspecifically those testing positive for human epidermal growth factor receptor 2 (HER2). A recent innovation in breast cancer biomarkers seeks the HER3 receptor instead, which could mean more comprehensive breast cancer imaging and potential treatments, say experts presenting data during the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

Breast cancer is one of the most prevalent forms of cancer among women. Certain kinds of tumors have been found to be more aggressive and associated with less than favorable prognoses compared to others. HER2 positive tumors are a hallmark of high-risk breast cancer. Emerging molecular imaging agents join tumor-seeking antibodies and signaling radioisotopes in one radiopharmaceutical that is injected at the time of imaging in order to track and report active receptors.

One of these investigational agents, known in the lab as Cu-64 DOTA-HER3 F(ab')2, does just that by hunting down HER3, a messenger that has been shown to speak for HER2-positive cancers in multiple tissue models when used in conjunction with a scanner called a positron emission tomography (PET) imaging system. This could encourage better, more personalized care for breast cancer patients.

"HER3 is thought to be an important mediator of resistance to the HER2 inhibitors class of anti-cancer therapies, which are used to treat HER2-positive breast cancer representing approximately 20 percent of all breast cancers," said principal author Eric P. Wehrenberg-Klee, MD, from Massachusetts General Hospital in Boston, Mass. "Imaging of HER3 expression may allow for better understanding of how prevalent HER3 over-expression is among HER2 positive breast cancer patients, which in turn may allow for appropriate patient selection for the addition of HER3 inhibitors currently in clinical development."

The researchers expect that it may be another year or two before the agent will reach regulatory approval and enter general clinical practice.

An estimated 232,670 new cases of invasive breast cancer will be diagnosed in women this year, according to 2014 data from the American Cancer Society. Approximately 40,000 women will die from breast cancer this year.


'/>"/>

Contact: Kimberly Brown
kbrown@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Molecular breast imaging protocol unmasks more cancer
2. Scientists generate long-sought molecular map of critical genetic machinery
3. Scripps Florida scientists unravel the molecular secret of short, intense workouts
4. Molecular high-speed origami
5. International molecular screening program for metastatic breast cancer AURORA at IMPAKT
6. NIH scientist to receive Ross Prize in Molecular Medicine
7. Malfunction in molecular proofreader prevents repair of UV-induced DNA damage
8. Adjuvant chemotherapy increases markers of molecular aging in the blood of BC survivors
9. UNC researchers show cancer chemotherapy accelerates molecular aging
10. Big data tackles tiny molecular machines
11. Molecular aberration signals cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... ... announced it has been included by Gartner, Inc. in the Contact Center Infrastructure ... of Contact Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web ...
(Date:5/31/2016)... ... May 31, 2016 , ... The University of ... Intelligence (AI) and the latest in Clinical Patient Pod (CPP) technologies ... analytic outputs directly into the clinical workflow. These insights are empowering the more ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... commercial molecular diagnostics device that enables unprecedented portability and convenience. , The Cube ... four inches cubed in size, the Cube fits easily into any space, whether ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Global Wellness Summit ... predictions on the future of wellness, travel, spa and beauty in Europe. The organization ... beauty companies to leading economists and researchers - to forecast where wellness is headed ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Orthopaedic Research and Education Foundation ... , David G. Lewallen, MD, began his term as president in March, succeeding John ... MD, is OREF’s new president-elect. Richard F. Kyle, MD, will serve as chair, corporate ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 31, 2016 According to a ... (Scanners, Software), by Type (Human, Animal Pathology), by End ... Drug Discovery) - Global Forecasts to 2021", published by ... forecast period of 2016 to 2021. This market is ... USD 384.3 Million in 2016, at a CAGR of ...
(Date:5/31/2016)... 2016   Plexus Technology Group, LLC ... management systems (AIMS), is pleased to announce the ... President of Technology. In this new capacity, Mr. ... the company,s technological development. He will collaborate with ... the expansion of new products, product features and ...
(Date:5/31/2016)... BASEL, Switzerland , May 31, 2016 ... has announced the initiation of a first-in-human clinical trial ... class, fusion molecule - S101 is currently being developed ... phase 1 study is designed to evaluate the safety ... be conducted at several sites across the ...
Breaking Medicine Technology: